Pharvaris reported the FDA PDUFA target action date for deucrictibant IR is April 23, 2027; CREAATE part 1 topline data are expected in 1Q2027. Cash and cash equivalents were €283 million, and quarterly loss was €47.4 million.
PHVS · Pharvaris N.V.
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Price & Indicators
Key stats
- Short volume, last session
- 57%
- Price history
- Feb 2021 to Nov 2026
Latest documents
Pharvaris N.V. has an April 23rd, 2027 PDUFA date for on-demand treatment, plans CREATE topline data in the first quarter of next year, and expects parallel prophylaxis NDAs after collecting safety data in the first half of the 27th year.
Metrics snapshot
Useful current figures from the complete screener profile.
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders NeutralIllustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
PHVS
this stock
Pharvaris N.V.
|
$2.24B | +14.1% | — | — | 3.6% |
|
VRTX
Vertex Pharmaceuticals Inc
|
$132.01B | +14.8% | +46.2% | 33.5 | 1.9% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$95.52B | +19.6% | +20.8% | 20.4 | 2.1% |
|
MRNA
Moderna, Inc.
|
$80.65B | +575.9% | +4.3% | — | 8.2% |
|
CSLLY
Csl Ltd
|
$63.36B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every section- Filed
- Nov 12, 2026
- This year
- 16
Pharvaris reported the FDA PDUFA target action date for deucrictibant IR is April 23, 2027; CREAATE part 1 topline data are expected in 1Q2027. Cash and cash equivalents were €283 million, and quarterly loss was €47.4 million.
ViewPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| PHVS | -6.4% | +3.2% | +8.8% | -5.6% | +14.1% |
| SPY | -5.5% | -6.3% | -5.6% | -5.3% | +5.0% |
| vs SPY | -1.0% | +9.5% | +14.4% | -0.3% | +9.1% |